View in EDS

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.

Saved in:
Bibliographic Details
Title: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Authors: Tabernero J; Medical Oncology Department, Vall d'Hebron University Hospital, P. Vall d'Hebron, 119-129, 08035 Barcelona, Spain. jtabernero@vhebron.net, Van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, Van Laethem JL, Soulié P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O, de Gramont A
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2007 Nov 20; Vol. 25 (33), pp. 5225-32.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 18024868
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Tabernero+J%22">Tabernero J</searchLink>; Medical Oncology Department, Vall d'Hebron University Hospital, P. Vall d'Hebron, 119-129, 08035 Barcelona, Spain. jtabernero@vhebron.net<br /><searchLink fieldCode="AU" term="%22Van+Cutsem+E%22">Van Cutsem E</searchLink><br /><searchLink fieldCode="AU" term="%22Díaz-Rubio+E%22">Díaz-Rubio E</searchLink><br /><searchLink fieldCode="AU" term="%22Cervantes+A%22">Cervantes A</searchLink><br /><searchLink fieldCode="AU" term="%22Humblet+Y%22">Humblet Y</searchLink><br /><searchLink fieldCode="AU" term="%22André+T%22">André T</searchLink><br /><searchLink fieldCode="AU" term="%22Van+Laethem+JL%22">Van Laethem JL</searchLink><br /><searchLink fieldCode="AU" term="%22Soulié+P%22">Soulié P</searchLink><br /><searchLink fieldCode="AU" term="%22Casado+E%22">Casado E</searchLink><br /><searchLink fieldCode="AU" term="%22Verslype+C%22">Verslype C</searchLink><br /><searchLink fieldCode="AU" term="%22Valera+JS%22">Valera JS</searchLink><br /><searchLink fieldCode="AU" term="%22Tortora+G%22">Tortora G</searchLink><br /><searchLink fieldCode="AU" term="%22Ciardiello+F%22">Ciardiello F</searchLink><br /><searchLink fieldCode="AU" term="%22Kisker+O%22">Kisker O</searchLink><br /><searchLink fieldCode="AU" term="%22de+Gramont+A%22">de Gramont A</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309333%22">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</searchLink> [J Clin Oncol] 2007 Nov 20; Vol. 25 (33), pp. 5225-32.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309333 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1527-7755 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220732183X%22">0732183X </searchLink><i>NLM ISO Abbreviation: </i>J Clin Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=18024868
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/JCO.2007.13.2183
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 5225
    Titles:
      – TitleFull: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Tabernero J
      – PersonEntity:
          Name:
            NameFull: Van Cutsem E
      – PersonEntity:
          Name:
            NameFull: Díaz-Rubio E
      – PersonEntity:
          Name:
            NameFull: Cervantes A
      – PersonEntity:
          Name:
            NameFull: Humblet Y
      – PersonEntity:
          Name:
            NameFull: André T
      – PersonEntity:
          Name:
            NameFull: Van Laethem JL
      – PersonEntity:
          Name:
            NameFull: Soulié P
      – PersonEntity:
          Name:
            NameFull: Casado E
      – PersonEntity:
          Name:
            NameFull: Verslype C
      – PersonEntity:
          Name:
            NameFull: Valera JS
      – PersonEntity:
          Name:
            NameFull: Tortora G
      – PersonEntity:
          Name:
            NameFull: Ciardiello F
      – PersonEntity:
          Name:
            NameFull: Kisker O
      – PersonEntity:
          Name:
            NameFull: de Gramont A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 20
              M: 11
              Text: 2007 Nov 20
              Type: published
              Y: 2007
          Identifiers:
            – Type: issn-electronic
              Value: 1527-7755
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 33
          Titles:
            – TitleFull: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
              Type: main
ResultId 1